Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Change in Accured Expenses (2016 - 2026)

Corvus Pharmaceuticals' Change in Accured Expenses history spans 12 years, with the latest figure at $499000.0 for Q1 2026.

  • Quarterly Change in Accured Expenses rose 241.78% to $499000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Mar 2026, up 1657.0% year-over-year, with the annual reading at $2.8 million for FY2025, 1226.94% up from the prior year.
  • Change in Accured Expenses came in at $499000.0 for Q1 2026, down from $765000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.2 million in Q3 2022 to a low of -$1.9 million in Q1 2023.
  • The 5-year median for Change in Accured Expenses is $101000.0 (2024), against an average of -$5647.1.
  • Year-over-year, Change in Accured Expenses plummeted 481.53% in 2022 and then soared 895.51% in 2025.
  • Corvus Pharmaceuticals' Change in Accured Expenses stood at -$1.0 million in 2022, then skyrocketed by 42.37% to -$589000.0 in 2023, then rose by 16.81% to -$490000.0 in 2024, then skyrocketed by 256.12% to $765000.0 in 2025, then tumbled by 34.77% to $499000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Change in Accured Expenses are $499000.0 (Q1 2026), $765000.0 (Q4 2025), and $708000.0 (Q3 2025).